ArticlePharmaceuticals (Basel, Switzerland)2025
Bioequivalence Study of Two Oral Methocarbamol Formulations in Healthy Subjects Under Fasting Conditions: A Randomized, Open-Label, Crossover Clinical Trial.
Ana Ascaso-Del-Rio, Paola Camargo-Mamani, Inmaculada Gilaberte, Mónica Díez-Hochleitner, Leonor Laredo-Velasco, Teresa Iglesias-Hernangómez, María Rosario Salas-Butrón, Laura Galán Caballero, Iván Alejandro Díaz-Rengifo, Carla Pérez-Ingidua and 2 more
Abstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Ana Ascaso-Del-RioClinical Pharmacology Department, Hospital Clínico San Carlos, C/Prof Martín Lagos s/n, 28040 Madrid, Spain.ORCID 0000-0002-9159-3520 Inmaculada GilaberteClinical Research Department, Faes Farma, Av. Autonomía 10, 48940 Leioa, Spain.
Mónica Díez-HochleitnerClinical Research Department, Faes Farma, Av. Autonomía 10, 48940 Leioa, Spain.
Leonor Laredo-VelascoClinical Pharmacology Department, Hospital Clínico San Carlos, C/Prof Martín Lagos s/n, 28040 Madrid, Spain.
Teresa Iglesias-HernangómezClinical Pharmacology Department, Hospital Clínico San Carlos, C/Prof Martín Lagos s/n, 28040 Madrid, Spain.
María Rosario Salas-ButrónClinical Pharmacology Department, Hospital Clínico San Carlos, C/Prof Martín Lagos s/n, 28040 Madrid, Spain.
Laura Galán CaballeroClinical Pharmacology Department, Hospital Clínico San Carlos, C/Prof Martín Lagos s/n, 28040 Madrid, Spain.
Iván Alejandro Díaz-RengifoInstituto de Investigación Sanitaria del Hospital Clínico San Carlos, C/Prof Martín Lagos s/n, 28040 Madrid, Spain.ORCID 0000-0003-3959-8196 Carla Pérez-IngiduaClinical Pharmacology Department, Hospital Clínico San Carlos, C/Prof Martín Lagos s/n, 28040 Madrid, Spain.
Emilio Vargas-CastrillónClinical Pharmacology Department, Hospital Clínico San Carlos, C/Prof Martín Lagos s/n, 28040 Madrid, Spain.ORCID 0000-0003-4828-6004 Antonio Portolés-PérezClinical Pharmacology Department, Hospital Clínico San Carlos, C/Prof Martín Lagos s/n, 28040 Madrid, Spain.ORCID 0000-0002-5646-5275 Funding
Faes Farma (Spain) NA
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
bioequivalencebioequivalence studymethocarbamolmethocarbamol bioequivalencemethocarbamol pharmacokineticsRobaxin
Identifiers
PMID40143131
PMCPMC11946590
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390